Better Health,
Brighter Future
Newsroom
Careers
Investors
Patients
HCPs
Worldwide
Who We Are
About Takeda
How can we do more for our patients?
Everything at Takeda starts with this question.
Learn more
Company Information
Company Facts & Japan offices
History
Worldwide Offices
Executive Leadership
Positions
Takeda Global Headquarters
Life at Takeda
Design Concept
Where we work
Corporate Philosophy
Our People
Values and Corporate Governance
Corporate Governance
Risk & Crisis Management
Global Ethics & Compliance
Transparency Disclosures
From the CEO
Contact Us
Celebrating the grand opening of Takeda Global Headquarters
LEARN MORE
What We Do
Our Business
We will become a global, values-based, R&D-driven, biopharmaceutical leader
Learn more
Research & Development
Ecosystem for Health Innovation
Our Pipeline
Clinical Trials
Investigator Initiated Research
Areas of Focus
Oncology
Rare Diseases
Neuroscience
Gastroenterology
Plasma-Derived Therapies
Vaccines
Alliances & Partnerships
Partnering with Takeda
T-CiRA
Our Products
Manufacturing
Innovation Story
Access to Medicines
Our Approach and Our Position
Hear from Patients
Driving Impact with Partners
Pre- Approval Access
Suppliers
Sustainable Procurement
Supplier Code of Conduct
Supplier Diversity
Pharmaceutical Supply Chain Initiative
Supplier Qualification & Due Diligence
Shire Supplier Information
We focus on our core therapeutic areas.
LEARN MORE
Our Stories
Our Stories
A selection of stories related to Innovation, Caring and Heritage
Learn more
Innovation
Quality at Takeda
The Key Elements at the Heart of Our Innovation
Caring
Medicine for the World
Safeguarding Plant Diversity
Takeda at TICAD6
Going Beyond Medicines
Change the World
Healthcare for All
Shared Knowledge for a Better Life for All
Heritage
Keys to Aging Gracefully
Shared Knowledge for a Better Life for All
LEARN MORE
Corporate Responsibility
Takeda's CSR
Takeda is committed to creating corporate value by developing outstanding pharmaceutical products and conducting corporate citizenship activities.
LEARN MORE
Our CSR Philosophy
Human Rights
Labor
Environment
Anti-Corruption
Activities
Global CSR Program
Takeda Chair in Global Child Health
SDGs
Takeda Initiative for the Global Fund
HERhealth
Global Relay for Life
Digital Birth Registration
Corporate Citizenship Videos
Sustainable Value Report
How We Drive: Sustainable Value
TAKEDA LIFE THEATER
Takeda is committed to contributing to the long-term health of people through disease prevention.
LEARN MORE
HOME
Newsroom
News Releases
Share:
Newsroom
News Releases
In the News
Featured Topics
Corporate Materials
Social Media
Message from the CEO
News Releases
Enter
All
Last 12 months
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
March 2020
March 23, 2020
3/23/2020
Takeda Receives Approval of Entyvio® (Vedolizumab) in China for the Treatment of Patients with Moderate to Severe Active Ulcerative Colitis (UC) and Crohn's Disease (CD)
March 17, 2020
3/17/2020
The Lancet publishes papers from two studies of Takeda’s dengue vaccine candidate
March 10, 2020
3/10/2020
Takeda Provides Update on TOURMALINE-MM2 Phase 3 Trial
March 4, 2020
3/4/2020
TAKEDA COMPLETES SALE OF SELECT OTC AND NON-CORE ASSETS TO STADA
March 4, 2020
3/4/2020
Takeda Initiates Development of a Plasma-Derived Therapy for COVID-19
March 2, 2020
3/2/2020
Takeda Receives Positive CHMP Opinion for ALUNBRIG® (brigatinib) as a First-Line Treatment for ALK+ Non-Small Cell Lung Cancer
March 2, 2020
3/2/2020
TAKEDA COMPLETES SALE OF SELECT OTC AND NON-CORE ASSETS TO ACINO
March 2, 2020
3/2/2020
TAKEDA AGREES TO DIVEST SELECT OTC AND NON-CORE ASSETS IN LATIN AMERICA TO HYPERA PHARMA FOR $825 MILLION USD
February 2020
February 28, 2020
2/28/2020
Takeda Receives Positive CHMP Opinion for Subcutaneous Vedolizumab as Maintenance Therapy in UC or CD
1
2
3
4
5
・For Shire news releases, click here
TOP
